ClinicalTrials.gg
Active, not recruitingNCT05870917Updated Nov 4, 2026

A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia

A Phase 2 interventional study of anti-BCMA CAR-T and VRD-based Regimen in Plasma Cell Leukemia, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Phase 2, Interventional, and Treatment

How we know

Updated Nov 4, 2026Primary completion movedEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Leukemia, Plasma Cell with a site in China — 17 open to participants now, 18 under way, none of them phase 3. Leukemia, Plasma Cell · China.

Enrollment
6th of 19
25 · median 24
Started
2023
with 5 others
Phase 2
7 of 20
5 open now
Primary completion
2025-09
later than 0 of 17 live
Registered
8th of 20
by date
Lead sponsor
8 of 20
Institute of Hematology & Blood Diseases Hospital, China

Among the 20 studies in Leukemia, Plasma Cell with a site in China, this one is the 6th largest by enrollment of the 19 interventional ones that give a count, is one of 6 that started in 2023, is one of 7 in phase 2, reaches primary completion later than 0 of the 17 other live ones, and was the 8th registered.

Leukemia, Plasma Cell

60 studies on the registry are indexed under Leukemia, Plasma Cell; 33 are open to participants now.

Browse Leukemia, Plasma Cell studies →

Open to participants now

17 of the 20 studies in Leukemia, Plasma Cell with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 29 Leukemia, Plasma Cell studies recruiting now, 12 (41%) set no upper age limit and 13 (45%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Leukemia, Plasma Cell with a site in China, or all of them as a file.
02

Study summary

This is a single-arm, open-label study to evaluate the efficacy and safety of VRD-based Regimen (Bortezomib, Lenalidomide and Dexamethasone) combined with CART-ASCT-CART2 in Chinese patients with newly diagnosed primary plasma cell leukemia.

Read the detailed description

The study is a prospective, single-arm, single-centre, phase II study designed to evaluate the efficacy and safety of treatment with VRD-based Regimen (Bortezomib, Lenalidomide and Dexamethasone) in combination with CART-ASCT-CART2 in Chinese patients with newly diagnosed primary plasma cell leukemia. Patients receive 3-4 cycles of induction therapy with VRD-based regimen followed by the first infusion of CAR-T cells. Patients then received 2-3 cycles of VR-based consolidation therapy, followed by ASCT and the second infusion of CAR-T cells. And R-based maintenance starts on day 100 after ASCT.

03

Conditions studied

  • Plasma Cell Leukemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary written before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
  2. Age ≥ 18 years and ≤ 65 years.
  3. (ECOG) performance status 0, 1, or 2.
  4. at least 3 months
  5. Definitive diagnosis of pPCL: meet the diagnosis criteria of multiple myeloma (refer to the Chinese guidelines for the diagnosis and management of multiple myeloma (revised 2022) criteria) and meeting any of the following:

    1. the proportion of tumor plasma cells in peripheral blood leukocytes ≥ 5%;
    2. absolute value of peripheral blood tumorigenic plasma cells exceeds 2×10\^9/L.
  6. Patients have not received previous anti-myeloma related therapy.
  7. , as defined by at lease one of the following:

    1. Serum monoclonal paraprotein (M-protein) level ≥5g/L.
    2. urine M-protein level ≥200 mg/24 hours.
    3. If the serum and urine M-protein are unmeasurable, abnormal serum free light chain (FLC) ratio and affected FLC ≥10 mg/dL.
  8. Bone marrow sample is confirmed as BCMA-positive by flow cytometry or pathological examination.
  9. Routine blood tests (performed within 7 days, no RBC transfusion, no G-CSF/GM-CSF/ agonists, no drug correction within 14 days before screening, no PLT transfusion within 7 days) : ≥ 1.0 x 10\^9/L, PLT ≥ 50 x 10\^9/L.
  10. All screening blood biochemistry: tests should be performed according to the protocol and within 14 days before enrollment. Screening laboratory values must meet the following criteria:

    1. Total \<1.5 x (ULN);
    2. (ALT) and aspartate aminotransferase (AST);
    3. ≥ 50mL/min (calculated using Cockroft-Gault formula).
  11. Patients must be able to take prophylactic anticoagulant therapy as recommended by the study.
  12. The woman is not breastfeeding, is not pregnant and agrees not to be pregnant during the study period and for the following 12 months. Male patients agreed that their spouse would not become pregnant during the study period and for 12 months thereafter.
  13. Willing and able to complete the study procedures and follow-up examinations.

Exclusion criteria

Exclusion Criteria:

  1. Secondary plasma cell leukemia.
  2. With central nervous system (CNS) involvement.
  3. Ineligible for stem cell transplantation, such as severe cardiopulmonary disorders.
  4. Known intolerant, allergic, or resistant to , bortezomib, lenalidomide, Venetoclax, Selinexor and BCMA-CART cellular products.
  5. Patients had major surgery within 2 weeks before randomization (for example, general anesthesia), or is not fully recovered from the surgery, or surgery is arranged during study period.
  6. Patients with unstable or active cardiovascular system disease, meeting any of the following:

    1. Unstable angina pectoris, symptomatic myocardial ischaemia, myocardial infarction or coronary artery reconstruction within 180 days prior to the first dose.
    2. Uncontrolled hypertension (>140/90 mmHg with blood pressure fluctuations of more than 180/100 mmHg over a 6-month period).
    3. Uncontrolled and conduction abnormalities (e.g. patients with ventricular arrhythmias controlled by antiarrhythmic medication), not excluding patients with 1st degree atrioventricular (AV) block or asymptomatic left anterior bundle branch block/right bundle branch block (LAFB/RBBB)).
    4. Congestive heart failure (CHF) classification ≥ grade 3 as defined by the (NYHA).
    5. (LVEF) \<50% on echocardiography.
    6. History of stroke or intracranial haemorrhage within 12 months prior to screening.
    7. Presence of a serious thrombotic event prior to treatment.
  7. Known positive serology for or HIV seropositivity.
  8. Active or C infection. Screening requires serologic testing for hepatitis. If hepatitis B surface antigen and hepatitis B core antibody were positive, a negative DNA polymerase chain reaction (PCR) result was needed before enrollment (after anti-hepatitis B therapy, a negative DNA polymerase PCR result was confirmed before enrollment). If the antibody was positive, the RNA PCR test should be negative prior to enrollment.
  9. Ongoing active infection.
  10. Prior history of , unless free of the disease for ≥ 5 years.
  11. Pregnant or breast feeding females.
  12. Any active gastrointestinal dysfunction that affects the patient's ability to swallow tablets, or any active gastrointestinal dysfunction that may affect the absorption of the studied treatment medication.
  13. According to the researcher's judgment, any condition including but not limited to serious mental illness, medical illness, or other symptoms/conditions that may affect study treatment, compliance, or the capability of providing .
  14. Necessary medication or supportive therapy is with study treatment.
  15. Any other medical condition or comorbidity that might interfere with subject's participation.
  16. Patients undergoing other experimental therapies.
  17. Patients are not willing to or cannot comply with study scheme.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    VRD-based regimen Combined CART-ASCT-CART2

    VRD:Bortezomib, Lenalidomide and Dexamethasone Bortezomib SC 1.3mg/sqm on day 1,8,15,22, Lenalidomide oral 25 mg on day 1-21, and Dexamethasone 40mg on day 1,8,15,22 in a 28-day cycle. Autologous BCMA-directed CAR T cells: two sequential intravenous infusions of the same product in each patient, either YK-BB-002 at a target dose of (2-4) × 10⁶ ± 20% CAR-positive T cells/kg or equecabtagene autoleucel at a planned dose of 1.0 × 10⁶ CAR-positive T cells/kg. Participants will receive VRD-based induction, first CAR-T infusion, VR-based consolidation, ASCT followed by the second CAR-T infusion, and R-based maintenance.

    Biological: anti-BCMA CAR-T · Drug: VRD-based Regimen

Interventions

  • Biologicalanti-BCMA CAR-T

    Patients receive two sequential intravenous infusions of one of two BCMA-directed autologous CAR T-cell products, with the same product used for both infusions in each patient: YK-BB-002, (2-4) × 10⁶ ± 20% CAR-positive T cells/kg; Equecabtagene autoleucel: Planned dose of 1.0 × 10⁶ CAR-positive T cells/kg.

  • DrugVRD-based Regimen

    Bortezomib, Lenalidomide and Dexamethasone

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS)

    Is defined as time from first induction date to first documentation of PD, or death due to any cause, whichever occurs first.

    Time frame: 1 year

  2. Safety and Tolerability

    The incidence of treatment-emergent adverse events (TEAEs)

    Time frame: 2 year

Secondary outcomes

  1. Complete response rate (CRR)

    CR or better is defined as percentage of participants who achieve a CR response or Stringent Complete Response (sCR) response according to IMWG criteria

    Time frame: after induction therapy, 1 and 3 month after first CAR-T cell infusion, 1 and 3 month after the second CAR-T cell infusion

  2. Overall survival (OS)

    Is defined as time from first induction date to time of death due to any cause

    Time frame: 2 year

  3. MRD-negative Rate

    MRD negative by flow cytometry

    Time frame: after induction therapy, 1 and 3 month after first CAR-T cell infusion, 1 and 3 month after the second CAR-T cell infusion

  4. Duration of Remission (DOR)

    Duration from the first evaluation of at least partial remission (PR) to the onset of disease progression or death due to disease progression (whichever occurs first)

    Time frame: 2 year

  5. Overall response rate (ORR)

    ORR (including sCR/CR/VGPR/PR, based on IMWG criteria)

    Time frame: after induction therapy, 1 and 3 month after first CAR-T cell infusion, 1 and 3 month after the second CAR-T cell infusion

Other outcomes

  1. The CART cell duration in vivo

    The copies of BCMA-CART DNA in peripheral blood with qPCR method

    Time frame: 1 year

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from May 2023 to primary completion in Sep 2025, 27 months.

Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Sep 2025, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2023
First posted
May 23, 2023
StartActual
May 23, 2023
Primary completionActual
Sep 18, 2025was Jun 2026
CompletionEst.
Apr 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 2026→Sep 18, 2025 (actual)
Nov 4, 2026
Enrollment
20 (estimated)→25 (actual)
Nov 4, 2026
Interventions
Added Drug: VRD-based Regimen
Nov 4, 2026
Primary outcomes
1 removed
What changed in the outcomes
  • RemovedOverall response rate (ORR)Time frame: after induction therapy, 1 month after the first CAR-T cell transfusion, the consolidation therapy ends, 6 months after the second CAR-T cell transfusion
Nov 4, 2026
Secondary outcomes
3 time frame changed, 1 added
What changed in the outcomes
  • AddedOverall response rate (ORR)Time frame: after induction therapy, 1 and 3 month after first CAR-T cell infusion, 1 and 3 month after the second CAR-T cell infusion
  • Time frameComplete response rate (CRR)after induction therapy, 1 month after the first CAR-T cell transfusion, the consolidation therapy ends, 6 months after the second CAR-T cell transfusion → after induction therapy, 1 and 3 month after first CAR-T cell infusion, 1 and 3 month after the second CAR-T cell infusion
  • Time frameOverall survival (OS)1 year → 2 year
  • Time frameMRD-negative Rateafter induction therapy, 1 month after the first CAR-T cell transfusion, the consolidation therapy ends, 6 months after the second CAR-T cell transfusion → after induction therapy, 1 and 3 month after first CAR-T cell infusion, 1 and 3 month after the second CAR-T cell infusion
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Primary completion Jun 2026→Sep 18, 2025 (now actual)
    Enrollment 20 (estimated)→25 (actual)
    Primary outcomes 1 removed
    What changed in the outcomes
    • RemovedOverall response rate (ORR)Time frame: after induction therapy, 1 month after the first CAR-T cell transfusion, the consolidation therapy ends, 6 months after the second CAR-T cell transfusion
    Secondary outcomes 3 time frame changed, 1 added
    What changed in the outcomes
    • AddedOverall response rate (ORR)Time frame: after induction therapy, 1 and 3 month after first CAR-T cell infusion, 1 and 3 month after the second CAR-T cell infusion
    • Time frameComplete response rate (CRR)after induction therapy, 1 month after the first CAR-T cell transfusion, the consolidation therapy ends, 6 months after the second CAR-T cell transfusion → after induction therapy, 1 and 3 month after first CAR-T cell infusion, 1 and 3 month after the second CAR-T cell infusion
    • Time frameOverall survival (OS)1 year → 2 year
    • Time frameMRD-negative Rateafter induction therapy, 1 month after the first CAR-T cell transfusion, the consolidation therapy ends, 6 months after the second CAR-T cell transfusion → after induction therapy, 1 and 3 month after first CAR-T cell infusion, 1 and 3 month after the second CAR-T cell infusion
    Interventions Added Drug: VRD-based Regimen
    + 3 other changes: verification date, description and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05870917
Responsible party
Sponsor
First posted
May 23, 2023
Start date
May 23, 2023
Primary completion
Sep 18, 2025
Completion
Apr 2027 (estimated)
Last update
Nov 4, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion